Democrats on the House Oversight Committee are pounding Big Pharma executives for price gouging, publishing an 18-month investigation of the soaring costs of select prescription medications and grilling  high-paid corporate leaders on whether those meds’ spiking prices were all too prevalent in the profit-ravenous drug industry.

The prescription medications targeted by the lawmakers included “Celgene and Bristol Myers Squibb’s Revlimid cancer treatment, which saw its price hiked 23 times since 2005, and Teva’s multiple sclerosis drug Copaxone, which went up in price 27 times since 2007,” reported the independent, nonpartisan Kaiser Health News service. “Those costs have little to do with research and development or industry efforts to help people afford medication, as drug companies often claim, according to the [congressional] probe.”